Cell Cycle Control and Check Points in Hematopoietic Stem Cells

Handbook of Stem Cells

Volumn 2, Issue , 2004, Pages 115-126

  Ruscetti, Francis W ^a   Bartelmez, Stephen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861737426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012436643-5/50100-0     Document Type: Chapter

References (160)

1. Jones R.J., Collector M.I., Barber J.P., Vala M.S., Fackler M.J., May W.S., Griffin C.A., Hawkins A.L., Zehnbauer B.A., Hilton J., Colvin O.M., Sharkis S.J. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 1996, 88:487-491.
2. Na Nakorn T., Traver D., Weissman I.L., Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J. Clin. Invest. 2002, 109:1579-1585.
3. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Scherer D.C., Beilhack G.F., Shizuru J.A., Weissman I.L. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 2003, 21:759-806.
4. Morrison S.J., Weissman I.L. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994, 1:661-673.
5. Gothot A., Pyatt R., McMahel J., Rice S., Srour E.F. Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0/G1 phase of the cell cycle. Blood 1997, 90:4384-4393.
6. Bertoncello I., Bradley T.R., Hodgson G.S., Dunlop J.M. The resolution, enrichment, and organization of normal bone marrow high proliferative potential colony-forming cell subsets on the basis of rhodamine-123 fluorescence. Exp. Hematol. 1991, 19:174-178.
7. Wolf N.S., Kone A., Priestley G.V., Bartelmez S.H. In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp. Hematol. 1993, 21:614-622.
8. Jordan C.T., Lemischka I.R. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990, 4:220-232.
9. Bradford G.B., Williams B., Rossi R., Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp. Hematol. 1997, 25:445-453.
10. Pietrzyk M.E., Priestley G.V., Wolf N.S. Normal cycling patterns of hematopoietic stem cell subpopulations: an assay using long-term in vivo BrdU infusion. Blood 1985, 66:1460-1462.
11. Cheshier S.H., Morrison S.J., Liao X., Weissman I.L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3120-3125.
12. Mahmud N., Devine S.M., Weller K.P., Parmar S., Sturgeon C., Nelson M.C., Hewett T., Hoffman R. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 2001, 97:3061-3068.
13. Osawa M., Hanada K., Hamada H., Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996, 273:242-245.
14. Bhatia M., Bonnet D., Murdoch B., Gan O.I., Dick J.E. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat. Med. 1998, 4:1038-1045.
15. Ortiz M., Wine J.W., Lohrey N., Ruscetti F.W., Spence S.E., Keller J.R. Functional characterization of a novel hematopoietic stem cell and its place in the c-Kit maturation pathway in bone marrow cell development. Immunity 1999, 10:173-182.
16. Ito C.Y., Li C.Y., Bernstein A., Dick J.E., Stanford W.L. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 2003, 101:517-523.
17. Goodell M.A., Rosenzweig M., Kim H., Marks D.F., Demaria M., Paradis G., Grupp S.A., Sieff C.A., Mulligan R.C., Johnson R.P. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med. 1997, 3:1337-1345.
18. Hao Q.L., Thiemann F.T., Petersen D., Smogorzewska E.M., Crooks G.M. Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. Blood 1996, 88:3306-3313.
19. Goodell M.A. Introduction: focus on hematology. CD34(+) or CD34(-): does it really matter?. Blood 1999, 94:2545-2547.
20. Sitnicka E., Ruscetti F.W., Priestley G.V., Wolf N.S., Bartelmez S.H. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of longterm repopulating hematopoietic stem cells. Blood 1996, 88:82-88.
21. Fortunel N., Batard P., Hatzfeld A., Monier M.N., Panterne B., Lebkowski J., Hatzfeld J. High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells. J. Cell Sci. 1998, 111:1867-1875. (Pt 13).
22. Fortunel N.O., Hatzfeld A., Hatzfeld J.A. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000, 96:2022-2036.
23. Wiesmann A., Kim M., Georgelas A., Searles A.E., Cooper D.D., Green W.F., Spangrude G.J. Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp. Hematol. 2000, 28:128-139.
24. Yu J., Soma T., Hanazono Y., Dunbar C.E. Abrogation of TGF-beta activity during retroviral transduction improves murine hematopoietic progenitor and repopulating cell gene transfer efficiency. Gene Ther. 1998, 5:1265-1271.
25. Nigg E.A. Cell cycle regulation by protein kinases and phosphatases. Ernst Schering Res. Found. Workshop 2001, 34:19-46.
26. Steinman R.A. Cell cycle regulators and hematopoiesis. Oncogene 2002, 21:3403-3413.
27. Eisenman R.N. Deconstructing myc. Genes Dev. 2001, 15:2023-2030.
28. Aktas H., Cai H., Cooper G.M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell Biol. 1997, 17:3850-3857.
29. Matsushime H., Roussel M.F., Ashmun R.A., Sherr C.J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991, 65:701-713.
30. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
31. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12:3499-3511.
32. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1091-1096.
33. Pardee A.B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 1974, 71:1286-1290.
34. Shackelford R.E., Kaufmann W.K., Paules R.S. Oxidative stress and cell cycle checkpoint function. Free Radic. Biol. Med. 2000, 28:1387-1404.
35. Won K.A., Xiong Y., Beach D., Gilman M.Z. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9910-9914.
36. Baldin V., Lukas J., Marcote M.J., Pagano M., Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993, 7:812-821.
37. Quelle D.E., Ashmun R.A., Shurtleff S.A., Kato J.Y., Bar-Sagi D., Roussel M.F., Sherr C.J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993, 7:1559-1571.
38. Ando K., Ajchenbaum-Cymbalista F., Griffin J.D. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:9571-9575.
39. Herwig S., Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur. J. Biochem. 1997, 246:581-601.
40. Lukas J., Muller H., Bartkova J., Spitkovsky D., Kjerulff A.A., Jansen-Durr P., Strauss M., Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 1994, 125:625-638.
41. Sage J., Mulligan G.J., Attardi L.D., Miller A., Chen S., Williams B., Theodorou E., Jacks T. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 2000, 14:3037-3050.
42. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000, 14:2393-2409.
43. Dou Q.P., Zhao S., Levin A.H., Wang J., Helin K., Pardee A.B. G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J. Biol. Chem. 1994, 269:1306-1313.
44. Botz J., Zerfass-Thome K., Spitkovsky D., Delius H., Vogt B., Eilers M., Hatzigeorgiou A., Jansen-Durr P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol. Cell Biol. 1996, 16:3401-3409.
45. Furukawa Y., Terui Y., Sakoe K., Ohta M., Saito M. The role of cellular transcription factor E2F in the regulation of cdc2 mRNA expression and cell cycle control of human hematopoietic cells. J. Biol Chem. 1994, 269:26,249-26,258.
46. Lee H.H., Chiang W.H., Chiang S.H., Liu Y.C., Hwang J., Ng S.Y. Regulation of cyclin D1, DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle. Gene Expr. 1995, 4:95-109.
47. Johnson D.G., Ohtani K., Nevins J.R. Auto-regulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 1994, 8:1514-1525.
48. Dou Q.P., Levin A.H., Zhao S., Pardee A.B. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res. 1993, 53:1493-1497.
49. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 1998, 18:753-761.
50. Blagosklonny M.V., Prabhu N.S., El-Deiry W.S. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 1997, 57:320-325.
51. Mitchell K.O., El-Deiry W.S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 1999, 10:223-230.
52. Wells J., Yan P.S., Cechvala M., Huang T., Farnham P.J. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene 2003, 22:1445-1460.
53. Vairo G., Livingston D.M., Ginsberg D. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 1995, 9:869-881.
54. Williams C.D., Linch D.C., Watts M.J., Thomas N.S. Characterization of cell cycle status and E2F complexes in mobilized CD34+ cells before and after cytokine stimulation. Blood 1997, 90:194-203.
55. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 2002, 3:11-20.
56. Leone G., Degregori J., Yan Z., Jakoi L., Ishida S., Williams R.S., Nevins J.R. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Gene Dev. 1998, 12:2120-2130.
57. Blagosklonny M.V., Pardee A.B. The restriction point of the cell cycle. Cell Cycle 2002, 1:103-110.
58. Zandstra P.W., Lauffenburger D.A., Eaves C.J. A ligand-receptor signaling threshold model of stem cell differentiation control: a biologically conserved mechanism applicable to hematopoiesis. Blood 2000, 96:1215-1222.
59. Jacobsen S.E., Ruscetti F.W., Ortiz M., Gooya J.M., Keller J.R. The growth response of Lin-Thy-1+ hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors. Exp. Hematol. 1994, 22:985-989.
60. Kato J.Y., Sherr C.J. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11513-11517.
61. Ekholm S.V., Reed S.I. Regulation of G(1) cyclindependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 2000, 12:676-684.
62. Vidal A., Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene 2000, 247:1-15.
63. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., Sherr C.J. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo. J. 1999, 18:1571-1583.
64. Zhang F., Monkkonen M., Roth S., Laiho M. TGF-beta induced G(1) cell cycle arrest requires the activity of the proteasome pathway. Transforming growth factor. Exp. Cell Res. 2002, 281:190-196.
65. Ciarallo S., Subramaniam V., Hung W., Lee J.H., Kotchetkov R., Sandhu C., Milic A., Slingerland J.M. Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor betamediated G(1) arrest. Mol. Cell Biol. 2002, 22:2993-3002.
66. Schorl C., Sedivy J.M. Loss of protooncogene c-Myc function impedes G(1) phase progression both before and after the restriction point. Mol. Biol Cell. 2003, 14:823-835.
67. Seoane J., Pouponnot C., Staller P., Schader M., Eilers M., Massague J. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 2001, 3:400-408.
68. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Moroy T., Bartek J., Massague J., Hanel F., Eilers M. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 2001, 3:392-399.
69. Gartel A.L., Ye X., Goufman E., Shianov P., Hay N., Najmabadi F., Tyner A.L. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4510-4515.
70. Chen C.R., Kang Y., Siegel P.M., Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002, 110:19-32.
71. Ducos K., Panterne B., Fortunel N., Hatzfeld A., Monier M.N., Hatzfeld J. p21(cip1) mRNA is controlled by endogenous transforming growth factor-beta1 in quiescent human hematopoietic stem/progenitor cells. J. Cell Physiol. 2000, 184:80-85.
72. Hu P.P., Shen X., Huang D., Liu Y., Counter C., Wang X.F. The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta. J. Biol. Chem. 1999, 274:35381-35387.
73. Bang O.S., Ruscetti F.W., Lee M.H., Kim S.J., Birchenall-Roberts M.C. Transforming growth factor-beta1 modulates p107 function in myeloid cells: correlation with cell cycle progression. J. Biol. Chem. 1996, 271:7811-7819.
74. Lecouter J.E., Kablar B., Hardy W.R., Ying C., Megeney L.A., May L.L., Rudnicki M.A. Strain-dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene. Mol. Cell Biol. 1998, 18:7455-7465.
75. Humbert P.O., Rogers C., Ganiatsas S., Landsberg R.L., Trimarchi J.M., Dandapani S., Brugnara C., Erdman S., Schrenzel M., Bronson R.T., Lees J.A. E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol. Cell 2000, 6:281-291.
76. Latres E., Malumbres M., Sotillo R., Martin J., Ortega S., Martin-Caballero J., Flores J.M., Cordon-Cardo C., Barbacid M. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000, 19:3496-3506.
77. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., Scadden D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
78. Cheng T., Rodrigues N., Dombkowski D., Stier S., Scadden D.T. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat. Med. 2000, 6:1235-1240.
79. Shiyanov P., Bagchi S., Adami G., Kokontis J., Hay N., Arroyo M., Morozov A., Raychaudhuri P. p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol. Cell Biol. 1996, 16:737-744.
80. Iavarone A., Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997, 387:417-422.
81. Petritsch C., Beug H., Balmain A., Oft M. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 2000, 14:3093-3101.
82. Cao Z., Flanders K.C., Bertolette D., Lyakh L.A., Wurthner J.U., Parks W.T., Letterio J.J., Ruscetti F.W., Roberts A.B. Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 2003, 101:498-507.
83. Kulkarni A.B., Ward J.M., Yaswen L., Mackall C.L., Bauer S.R., Huh C.G., Gress R.E., Karlsson S. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 1995, 146:264-275.
84. Letterio J.J., Geiser A.G., Kulkarni A.B., Dang H., Kong L., Nakabayashi T., Mackall C.L., Gress R.E., Roberts A.B. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 1996, 98:2109-2119.
85. Leveen P., Larsson J., Ehinger M., Cilio C.M., Sundler M., Sjostrand L.J., Holmdahl R., Karlsson S. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 2002, 100:560-568.
86. Friedberg E.C. Relationships between DNA repair and transcription. Annu. Rev. Biochem. 1996, 65:15-42.
87. Hartwell L.H., Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246:629-634.
88. Kastan M.B. Checkpoint controls and cancer. Introduction. Cancer Surv. 1997, 29:1-6.
89. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
90. Zhang H., Hannon G.J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 1994, 8:1750-1758.
91. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S., Nishimoto T., Morgan D.O., Franza B.R., Roberts J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992, 257:1689-1694.
92. Dulic V., Lees E., Reed S.I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992, 257:1958-1961.
93. Resnitzky D., Hengst L., Reed S.I. Cyclin Aassociated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol. Cell Biol. 1995, 15:4347-4352.
94. Rotman G., Shiloh Y. ATM: A mediator of multiple responses to genotoxic stress. Oncogene 1999, 18:6135-6144.
95. Tibbetts R.S., Brumbaugh K.M., Williams J.M., Sarkaria J.N., Cliby W.A., Shieh S.Y., Taya Y., Prives C., Abraham R.T. A role for ATR in the DNA damageinduced phosphorylation of p53. Genes Dev. 1999, 13:152-157.
96. Lukas C., Sorensen C.S., Kramer E., Santoni-Rugiu E., Lindeneg C., Peters J.M., Bartek J., Lukas J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999, 401:815-818.
97. Lukas C., Bartkova J., Latella L., Falck J., Mailand N., Schroeder T., Sehested M., Lukas J., Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 2001, 61:4990-4993.
98. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
99. Hansen R., Oren M. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 1997, 7:46-51.
100. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell Biol. 1984, 4:1689-1694.
101. Maki C.G., Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell Biol. 1997, 17:355-363.
102. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994, 8:2540-2551.
103. Shackelford R.E., Innes C.L., Sieber S.O., Heinloth A.N., Leadon S.A., Paules R.S. The Ataxia telangiectasia gene product is required for oxidative stress-induced G1 and G2 checkpoint function in human fibroblasts. J. Biol. Chem. 2001, 276:21,951-21,959.
104. Khanna K.K., Beamish H., Yan J., Hobson K., Williams R., Dunn I., Lavin M.F. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene 1995, 11:609-618.
105. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 84:1169-1174.
106. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71:587-597.
107. Lane D.P., Hall P.A. MDM2-arbiter of p53's destruction. Trends Biochem. Sci. 1997, 22:372-374.
108. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
109. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
110. Kapoor M., Hamm R., Yan W., Taya Y., Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 2000, 19:358-564.
111. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
112. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537.
113. Adams P.D., Sellers W.R., Sharma S.K., Wu A.D., Nalin C.M., Kaelin W.G. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell Biol. 1996, 16:6623-6633.
114. Gu Y., Rosenblatt J., Morgan D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 1992, 11:3995-4005.
115. Tiefenbrun N., Melamed D., Levy N., Resnitzky D., Hoffman I., Reed S.I., Kimchi A. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol. Cell Biol. 1996, 16:3934-3944.
116. Terada Y., Tatsuka M., Jinno S., Okayama H. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. Nature 1995, 376:358-362.
117. Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506.
118. Harrington E.A., Bruce J.L., Harlow E., Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11945-11950.
119. Samuel T., Weber H.O., Funk J.O. Linking DNA damage to cell cycle checkpoints. Cell Cycle 2002, 1:162-168.
120. Knudsen K.E., Booth D., Naderi S., Sever-Chroneos Z., Fribourg A.F., Hunton I.C., Feramisco J.R., Wang J.Y., Knudsen E.S. RB-dependent S-phase response to DNA damage. Mol. Cell Biol. 2000, 20:7751-7763.
121. Beamish H., Williams R., Chen P., Lavin M.F. Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation. J. Biol. Chem. 1996, 271:20,486-20,493.
122. Parker L.L., Sylvestre P.J., Byrnes M.J., Liu F., Piwnica-Worms H. Identification of a 95-kDa WEE1-like tyrosine kinase in HeLa cells. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9638-9642.
123. Mueller P.R., Coleman T.R., Kumagai A., Dunphy W.G. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995, 270:86-90.
124. Strausfeld U., Labbe J.C., Fesquet D., Cavadore J.C., Picard A., Sadhu K., Russell P., Doree M. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 1991, 351:242-245.
125. Liu J.H., Wei S., Burnette P.K., Gamero A.M., Hutton M., Djeu J.Y. Functional association of TGF-beta receptor II with cyclin B. Oncogene 1999, 18:269-275.
126. Vairapandi M., Balliet A.G., Hoffman B., Liebermann D.A. GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. J. Cell Physiol. 2002, 192:327-338.
127. Furnari B., Blasina A., Boddy M.N., McGowan C.H., Russell P. Cdc25 inhibited in vivo and in vitro by checkpoint kinases Cds1 and Chk1. Mol. Biol Cell. 1999, 10:833-845.
128. O'Connor P.M., Ferris D.K., Hoffmann I., Jackman J., Draetta G., Kohn K.W. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9480-9484.
129. Uckun F.M., Tuel-Ahlgren L., Waddick K.G., Jun X., Jin J., Myers D.E., Rowley R.B., Burkhardt A.L., Bolen J.B. Physical and functional interactions between Lyn and p34cdc2 kinases in irradiated human B-cell precursors. J. Biol. Chem. 1996, 271:6389-6397.
130. Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401:616-620.
131. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998, 282:1893-1897.
132. Weinert T. A DNA damage checkpoint meets the cell cycle engine. Science 1997, 277:1450-1451.
133. Zampetti-Bosseler F., Scott D. Cell death, chromosome damage and mitotic delay in normal human, ataxia telangiectasia and retinoblastoma fibroblasts after x- irradiation. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1981, 39:547-558.
134. Muschel R.J., Zhang H.B., McKenna W.G. Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. Cancer Res. 1993, 53:1128-1135.
135. Naderi S., Hunton I.C., Wang J.Y. Radiation dosedependent maintenance of G(2) arrest requires retinoblastoma protein. Cell Cycle 2002, 1:193-200.
136. Cicchillitti L., Fasanaro P., Biglioli P., Capogrossi M.C., Martelli F. Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J. Biol. Chem. 2003, 278:19,509-19,517.
137. O'Connor P.M., Ferris D.K., Pagano M., Draetta G., Pines J., Hunter T., Longo D.L., Kohn K.W. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem. 1993, 268:8298-8308.
138. Poon R.Y., Jiang W., Toyoshima H., Hunter T. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J. Biol. Chem. 1996, 271:13,283-13,291.
139. Quelle F.W., Wang J., Feng J., Wang D., Cleveland J.L., Ihle J.N., Zambetti G.P. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev. 1998, 12:1099-1107.
140. Eapen A.K., Henry M.K., Quelle D.E., Quelle F.W. Dna damage-induced G(1) arrest in hematopoietic cells is overridden following phosphatidylinositol 3-kinase-dependent activation of cyclin-dependent kinase 2. Mol. Cell Biol. 2001, 21:6113-6121.
141. Henry M.K., Lynch J.T., Eapen A.K., Quelle F.W. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 2001, 98:834-841.
142. Nimbalkar D., Henry M.K., Quelle F.W. Cytokine activation of phosphoinositide 3-kinase sensitizes hematopoietic cells to cisplatin-induced death. Cancer Res. 2003, 63:1034-1039.
143. Kandel E.S., Skeen J., Majewski N., Di Cristofano A., Pandolfi P.P., Feliciano C.S., Gartel A., Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol. Cell Biol. 2002, 22:7831-7841.
144. McKinnon P.J. Ataxia-telangiectasia: An inherited disorder of ionizing-radiation sensitivity in man. Progress in the elucidation of the underlying biochemical defect. Hum. Genet. 1987, 75:197-208.
145. Scott D., Spreadborough A.R., Roberts S.A. Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heterozygotes. Int. J. Radiat. Biol. 1994, 66:S157-S163.
146. Ruscetti F.W., Sitnicka E., Letterio J.J., Walz T., Bartelmez S.H. Endogenous TGF-beta 1 is a direct regulator of the survival of long term repopulating murine stem cells in vitro. Blood 1999, 94:466A.
147. Ruscetti F.W., Bartelmez S.H. Transforming growth factor beta, pleiotropic regulator of hematopoietic stem cells: potential physiological and clinical relevance. Int. J. Hematol. 2001, 74:18-25.
148. Fan X., Valdimarsdottir G., Larsson J., Brun A., Magnusson M., Jacobsen S.E., ten Dijke P., Karlsson S. Transient disruption of autocrine TGF-beta signaling leads to enhanced survival and proliferation potential in single primitive humanhemopoietic progenitor cells. J. Immunol. 2002, 168:755-762.
149. Bartelmez S.H., Iversen P., Ruscetti F.W. Inhibition of endogenous transforming growth factor beta-1 in long-term repopulating hematopoietic stem cells by morpholino antisense oligo-nucleotides (MAS) prior to transplant accelerates engraftment while reducing the number of stem cells required for long-term repopulation. Blood 2000, 96:474A.
150. Cashman J.D., Eaves A.C., Raines E.W., Ross R., Eaves C.J. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta. Blood 1990, 75:96-101.
151. Dao M.A., Hwa J., Nolta J.A. Molecular mechanism of transforming growth factor beta-mediated cell-cycle modulation in primary human CD34(+) progenitors. Blood 2002, 99:499-506.
152. Stier S., Cheng T., Forkert R., Lutz C., Dombkowski D.M., Zhang J.L., Scadden D.T. Ex vivo targeting of p21Cip1/Waf1 permits relative expansion of human hematopoietic stem cells. Blood 2003, 102:1260-1266.
153. Caslini C., Shilatifard A., Yang L., Hess J.L. The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2797-2802.
154. Varnum-Finney B., Xu L., Brashem-Stein C., Nourigat C., Flowers D., Bakkour S., Pear W.S., Bernstein I.D. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. Med. 2000, 6:1278-1281.
155. Bjornsson J.M., Larsson N., Brun A.C., Magnusson M., Andersson E., Lundstrom P., Larsson J., Repetowska E., Ehinger M., Humphries R.K., Karlsson S. Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4. Mol. Cell Biol. 2003, 23:3872-3883.
156. Lessard J., Schumacher A., Thorsteinsdottir U., van Lohuizen M., Magnuson T., Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 1999, 13:2691-2703.
157. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., Morrison S.J., Clarke M.F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
158. Reya T., Duncan A.W., Ailles L., Domen J., Scherer D.C., Willert K., Hintz L., Nusse R., Weissman I.L. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:405-414.
159. Dao M.A., Taylor N., Nolta J.A. Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13,006-13,011.
160. Yagi M., Ritchie K.A., Sitnicka E., Storey C., Roth G.J., Bartelmez S. Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8126-8131.